# Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients

> **NCT01036399** · PHASE2 · TERMINATED · sponsor: **University of Bologna** · enrollment: 9 (actual)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01036399
- **Lead sponsor:** University of Bologna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11
- **Primary completion:** 2009-08
- **Final completion:** 2011-08
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The EC withdrawn the approval becuase of possible conflicts of interests between our Institute and Supporter (Celgene)
- **Last updated:** 2012-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01036399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01036399, "Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT01036399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*